5414x 🎁 Instant

: Established a strategic collaboration with Cepheid (a Danaher subsidiary) to develop automated infectious disease sequencing solutions. Leadership Update

: A refined commercial strategy identified high-priority opportunities in applied and research markets worth an estimated $13 to $14 billion .

: £13.0 million (+52.9%), driven by AMR and EMEAI growth. : Established a strategic collaboration with Cepheid (a

: 58.2%, slightly down from 58.8% in H1 2024 due to one-off inventory charges and currency headwinds, despite an underlying improvement of 525 basis points. Segment Growth :

: Continued advancement in national programs like NIHR Bioresource. Strategic and Operational Developments Gross Profit : £61

The full text and detailed report of this "paper" (regulatory announcement) include the following key sections and financial highlights:

: £72.1 million, a 22.1% increase compared to H1 2024 (£59.0 million). Gross Profit : £61.4 million, up 24% year-on-year. Gross Profit : £61.4 million

"5414X" is the RNS (Regulatory News Service) identifier for the released by Oxford Nanopore Technologies plc .